4-((1H-pyrrol-1-yl)methyl)benzonitrile | 143426-60-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-((1H-pyrrol-1-yl)methyl)benzonitrile
• 英文别名: N-(4-cyanobenzyl)-1H-pyrrole；4-(pyrrol-1-ylmethyl)benzonitrile
• CAS: 143426-60-2
• 化学式: C₁₂H₁₀N₂
• 分子量: 182.225
• InChiKey: PHDOLBTZSIIYSV-UHFFFAOYSA-N

物化性质

• 熔点：
  46-49 °C
• 沸点：
  329.6±25.0 °C(Predicted)
• 密度：
  1.03±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  28.7
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-((1H-pyrrol-1-yl)methyl)benzonitrile 在 盐酸 、 硫酸 、 一水合肼 作用下， 以 乙醇 为溶剂， 反应 51.0h， 生成 4-Pyrrol-1-ylmethyl-benzoic acid hydrazide
  参考文献：
  名称：

  Aromatic hydrazides as specific inhibitors of bovine serum amine oxidase

  摘要：

  New hydrazides were synthesized in search for specific inhibitors of bovine serum amine oxidase: a series of benzoic and phenylacetic acid hydrazides containing the 1H-imidazol-1-yl or the 1H-imidazol-1-ylmethyl group as (o, m, p)-substituent in the phenyl ring; an analogous series of p-substituted phenylhydrazides with 5 or 6-membered heterocyclic ring as substituent, and a series of similar phenylpropionic hydrazides. The longer and more flexible phenylacetic hydrazides, and to a somewhat lesser extent the phenylpropionic ones, were better specific inhibitors of bovine serum amine oxidase than the benzoic hydrazides, which were also bound by the enzyme with high affinity, but at a slow rate. Derivatives with p- and m -substituents were more reactive than the o-substituted ones. The chemical nature of the substituent was less important than its position in the phenyl ring and the presence of methylene spacers. These data point to the presence of a hydrophobic site at short distance from the protein carbonyl cofactor, so that simultaneous interaction of the 2 ends of the inhibitor molecule can occur at the 2 sites. The presence of the hydrophobic site was confirmed by the capability of some molecule deprived of the hydrazidic group to act as mild inhibitors. All hydrazides were less reactive by 2-3 orders of magnitude towards pig kidney diamine oxidase and FAD-dependent monoamine oxidase from rat brain mitochondria, while the other compounds showed similar inhibition power against all proteins. The specificity for the bovine enzyme seems therefore to be related to the concerted action of the 2 moieties of the inhibitor molecule.

  DOI：

  10.1016/0223-5234(92)90005-l
• 作为产物：
  描述：

  1-(4-cyanobenzyl)-3,5,7-triaza-1-azoniatricyclo[3.3.1.1^3,7]decane bromide 在 盐酸 、 4-二甲氨基吡啶 作用下， 以 吡啶 、 乙醇 、 水 、 溶剂黄146 为溶剂， 反应 50.0h， 生成 4-((1H-pyrrol-1-yl)methyl)benzonitrile
  参考文献：
  名称：

  Acid−Base Catalysis in the Synthesis of Arylmethylene and Alkylmethine Pyrroles

  摘要：

  DOI：

  10.1021/jo971365d

文献信息

• HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS
  申请人：Härter Michael

  公开号：US20110301122A1

  公开（公告）日：2011-12-08

  The present application relates to novel substituted aryl compounds, processes for their preparation, their use for treatment and/or prevention of diseases and their use for the preparation of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which arise from metabolic adaptation to hypoxic states. Such treatments can be carried out as monotherapy or also in combination with other medicaments or further therapeutic measures.

  本申请涉及新型取代芳基化合物，其制备方法，它们用于治疗和/或预防疾病以及用于制备治疗和/或预防疾病的药物，特别是用于治疗和/或预防过度增殖和血管生成性疾病以及那些由于代谢适应缺氧状态而引起的疾病。这种治疗可以作为单独治疗进行，也可以与其他药物或进一步的治疗措施结合使用。
• Aryl compounds with aminoalkyl substituents and their use
  申请人：Härter Michael

  公开号：US20110312930A1

  公开（公告）日：2011-12-22

  The present application relates to novel aryl compounds with aminoalkyl substituents, to processes for their preparation, to their use for treatment and/or prevention of diseases and to their use for the preparation of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which arise from metabolic adaptation to hypoxic states. Such treatments can be carried out as monotherapy or also in combination with other medicaments or further therapeutic measures.

  本申请涉及具有氨基烷基取代基的新型芳基化合物，涉及其制备方法，涉及它们用于治疗和/或预防疾病以及用于制备治疗和/或预防疾病的药物的用途，特别是用于治疗和/或预防过度增殖和血管生成性疾病以及那些由于代谢适应低氧状态而引起的疾病。这种治疗可以作为单独治疗进行，也可以与其他药物或进一步的治疗措施结合使用。
• Inhibitors of protein farnesyltransferase and squalene synthase
  申请人：Abbott Laboratories

  公开号：US05631401A1

  公开（公告）日：1997-05-20

  The present invention provides a compound of the formula ##STR1## or a pharmaceutically acceptable salt thereof, which are useful in inhibiting protein farnesyltransferase and the farnesylation of the oncogene protein Ras or inhibiting de novo squalene production resulting in the inhibition of cholesterol biosynthesis, processes for the preparation of the compounds of the invention in addition to intermediates useful in these processes, a pharmaceutical composition, and to methods of using such compounds.

  本发明提供了一种化合物，其化学式为##STR1##或其药用可接受的盐，该化合物在抑制蛋白质法尼基转移酶和致癌基因蛋白Ras的法尼基化或抑制新生角鲨烯产生以致使胆固醇生物合成受到抑制方面具有用处，还提供了制备本发明化合物的方法，以及这些方法中有用的中间体，一种药物组合物和使用这种化合物的方法。
• Inhibitors of squalene synthetase and protein farnesyltransferase
  申请人：Abbott Laboratories

  公开号：US05783593A1

  公开（公告）日：1998-07-21

  The present invention provides a compound of the formula ##STR1## which inhibit squalene synthetase and cholesterol biosynthesis and are useful in the treatment of e.g., hyperlipidaemia, atherosclerosis, or fungal infections, processes for the preparation of the compounds of the invention, intermediates useful in these processes, and pharmaceutical compositions containing the compounds.

  本发明提供了一种化合物的公式 ##STR1##，它抑制了角鲨烯合酶和胆固醇生物合成，并且在治疗高脂血症、动脉粥样硬化或真菌感染等方面具有用途，以及用于制备该发明化合物的方法、这些方法中有用的中间体，以及含有这些化合物的药物组合物。
• (4-Phenoxyphenyl)tetrazolecarboxamides and related compounds as dual inhibitors of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL)
  作者：Angela Holtfrerich、Walburga Hanekamp、Matthias Lehr

  DOI：10.1016/j.ejmech.2013.01.050

  日期：2013.5

  Inhibitors of the enzymes fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), the principle enzymes involved in the degradation of endogenous cannabinoids like anandamide and 2-arachidonoylglycerol, have potential utility in the treatment of several disorders including pain, inflammation and anxiety. In the present study, the effectivity and selectivity of eight known FAAH and MAGL

  脂肪酸酰胺水解酶（FAAH）和单酰基甘油脂酶（MAGL）的抑制剂是参与降解内源性大麻素（如anandamide和2-arachidonoylglycerol）的主要酶，在治疗包括疼痛，炎症和焦虑症在内的多种疾病中具有潜在的用途。 。在本研究中，通过体外测定了八种已知的FAAH和MAGL抑制剂对适当酶的抑制作用的选择性和有效性。在可比较的条件下工作的分析方法。由于许多已知的FAAH和MAGL抑制剂仅由结合了杂环系统的亲脂性支架组成，因此，通过将不同的杂环结构连接到相同的亲脂性骨架（即4-苯氧基苯）上，评估了它们对酶抑制的作用。在此研究中合成的最具活性的化合物之一是N，N-二甲基-5-（4-苯氧基苯基）-2 H-四唑-2-羧酰胺（16）（IC 50 FAAH：0.012μM; IC 50MAGL：0.028μM）。该抑制剂在亲脂性4-苯氧基苯基区域被系统修饰。结构-活性关系研究表明，通过用3-